Fennec Pharmaceuticals vs Invivyd
Invivyd is the larger business, with $53.4m of revenue in fiscal 2025 against $44.6m for Fennec Pharmaceuticals (1.2 times as much). Invivyd grew faster (110.5% against -6.1%). Fennec Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -21.8% against -98.2%.
| Latest fiscal year | Fennec PharmaceuticalsFENC, 2025 | InvivydIVVD, 2025 |
|---|---|---|
| Revenue | $44.6m | $53.4m |
| Revenue growth | -6.1% | 110.5% |
| Net income | −$9.7m | −$52.5m |
| Operating margin | — | -104.0% |
| Net margin | -21.8% | -98.2% |
| Return on equity | -65.8% | -34.0% |
| Free cash flow | −$12.5m | −$58.3m |
| Cash | $36.8m | $227m |
| Total debt | $19.4m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 35 | 122 |
| Market value | $377m | $169m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 19 sales | 1 buys, 20 sales |